Abstract: Provided is a T-cell receptor (TCR) that can bind to a KWVESIFLIF (SEQ ID NO: 38)-HLA A2402 complex, wherein the binding affinity thereof is at least 2 times that of a wild-type TCR. Further provided is a fusion molecule of the TCR with a therapeutic agent, which fusion molecule targets a tumor cell presenting the KWVESIFLIF (SEQ ID NO: 38)-HLA A2402 complex.

Abstract: Compositions comprising nanoparticles, nanoplexes or virus comprising isolated nucleic acid comprising nucleic acid encoding a mammalian, and methods of using the compositions, are provided.

Abstract: A device receives programming code, corresponding to a dynamic programming language, that is to be executed by a computing environment, and executes the programming code. When executing the programming code, the device maintains a program counter that identifies an execution location within the programming code, and select blocks of the programming code based on the program counter. The blocks correspond to segments of the programming code, and are associated with type-based constraints that relate to types of variables that are used by the block. When executing the programming code, the device also compiles the selected blocks, caches the compiled blocks along with the type-based constraints, generates linking information between certain ones of the compiled blocks based on the type-based constraints, and executes the compiled blocks in an order based on the program counter, the type-based constraints, and the linking information.